About BioDelivery Sciences International
BioDelivery Sciences ("BDSI") is a specialty pharmaceutical company
that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.
The development strategy focuses on utilization of the FDA’s 505(b)(2) approval process to potentially obtain timely and efficient approval of new formulations of previously approved therapeutics which incorporate the company's licensed drug delivery technologies.
BDSI's patented drug delivery technologies include:
- BEMA™ (or BioErodibleMucoAdhesive) drug delivery technology, which consists of a small dissolvable polymer film for application to mucosal membranes (inner lining of cheek) for transmucosal delivery of drugs for time critical conditions.
- Bioral® drug delivery technology, which is based upon a novel process of encapsulating or protecting a drug to facilitate oral dosing of drugs otherwise given by intravenous administration.
Utilizing its proprietary delivery technologies, BDSI is currently developing formulations of pharmaceuticals aimed principally at treatment opportunities in areas such as pain and infections.